Cell line · CVCL_0297
HEY
Cancer cell line, Homo sapiens. High grade ovarian serous adenocarcinoma. 32 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. HEY. Cell lines, record CVCL_0297. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_0297
On this page
Cell line
As Cellosaurus gives it.
- Name
- HEY
- Accession
- CVCL_0297
- RRID
- RRID:CVCL_0297
- Synonyms
- Hey
- Species
- Homo sapiens (Human)
- Sex
- Female
- Age at sampling
- Age unspecified
- Category
- Cancer cell line
- Diseases
- High grade ovarian serous adenocarcinoma (NCIt C105555)
- Derived from
- Ovary (in situ)
- Parent
- HX/62 (CVCL_4995)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers32
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Hsa_Circ_0000615-Encoded 250-Amino Acid Polypeptide Suppresses Epithelial Ovarian Cancer Progression via Promoting HMGB1 Nuclear Accumulation. | Oncol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The central precocious puberty-associated gene MKRN3 is a tumor suppressor regulating CSDE1 ubiquitination in ovarian cancer. | Oncogenesis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Disruption of the SNRPF-DDX24-E2F4 Feedback Loop Uncouples Splicing and Transcriptional Regulation to Suppress Ovarian Cancer Progression. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Multiomics profiling and experiments in preclinical models revealed RAD51-IN-1 as a synergistic potentiator of anlotinib sensitivity. | Sci Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The long noncoding RNA AC093895.1 promotes ovarian cancer formation and metastasis through a positive feedback network dependent on the transcription factor SOX4. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Tumor-homing nanoplatform for the co-delivery of triptolide and siRNA-A4B2 conspicuously overcomes peritoneum metastasis of ovarian cancer. | Cell Oncol (Dordr) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Laeverin is Cell-Surface Target for Liquid-Phase Metastasizing Cancer Cells. | Adv Sci (Weinh) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Differential regulation of FADS2 by EZH2 reveals a metabolic vulnerability in ovarian cancer treatment. | EBioMedicine | 2025 | Its Methods give the RRID and name the line | PubMed | |
| CD38 contributes to tumor progression and tumor microenvironment reshaping in epithelial ovarian cancer. | Transl Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Serum metabolic fingerprints encode functional biomarkers for ovarian cancer diagnosis: a large-scale cohort study. | EBioMedicine | 2025 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 32
See all 32 papersRelatives8
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Parent | HX/62 | CVCL_4995 | Cell lines | |
| Derived from it | HEY A4 | CVCL_L041 | Cell lines | |
| Derived from it | HEY A8 | CVCL_8878 | Cell lines | |
| Derived from it | HEY AS1 | CVCL_L040 | Cell lines | |
| Derived from it | HEY C2 | CVCL_X009 | Cell lines | |
| Derived from it | HEY-1B | CVCL_AZ64 | Cell lines | |
| Derived from it | HEY-T30 | CVCL_2Z96 | Cell lines | |
| Derived from it | HEY/GFP | CVCL_JZ11 | Cell lines |
Cell banks1
| Cell bank | Catalog number | Status |
|---|---|---|
| CLS | 305017 |
Source CLS
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0297
GET https://conductscience.org/api/cell-lines/v1/CVCL_0297/papers?page=2